

Special Issue

Radiotherapy and Chemotherapy for Cancers

Message from the Guest Editor

Chemotherapy and radiotherapy have long played a central role in cancer treatment. Particularly in locally advanced cancers, such as primary tumors and limited lymph node metastases, chemoradiotherapy and radiotherapy with curative intent have been used as the standard of care in many cancer types. Furthermore, in recent years, molecular targeted therapies and immunotherapies have been introduced as drug therapies. Especially in early-stage and locally advanced cancers, the combination of chemoradiotherapy with molecular targeted therapies and immunotherapies has been rigorously evaluated to improve outcomes. In this Special Issue, we focus on findings that can be applied to improve outcomes of cancer treatment with chemoradiotherapy and radiotherapy. In particular, it aims to summarize basic analysis, exploratory studies, and clinical trials for the combination of molecular targeted therapies and immunotherapies with chemoradiotherapy for early stage and locally advanced cancers.

Guest Editor

Dr. Hidehito Horinouchi

Department of Thoracic Oncology, National Cancer Center Hospital,
Tokyo, Japan

Deadline for manuscript submissions

closed (15 July 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/54408

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)